Contact Us | Directions | Referring a Patient

A leading comprehensive brain tumor program, using molecular diagnostic, gene expression analysis,
cutting edge clinical trials and advanced medical informatics to customize treatment plans for cancer patients.
 Latest Headlines
Focused therapy may be effective, less toxic way to treat brain tumors
Wed, 27 Jul 2016 05:14:05 GMT (News)
Brain tumor won't stop Purdue's Will Colmery
Mon, 25 Jul 2016 22:03:41 GMT (Indiana University ...)
Israeli researchers find way to detect cancer cells before becoming ...
Tue, 26 Jul 2016 11:19:54 GMT (Jerusalem Post Israel News)
Brain Tumor Patient Dies After Ziopharm Gene Therapy Injection
Fri, 15 Jul 2016 01:33:00 GMT (TheStreet.com)
Mice survive brain cancer tumors lacking key surface proteins ...
Sat, 23 Jul 2016 19:52:00 GMT (Science Daily)
Brain tumor survivor gives hope through experience
Wed, 20 Jul 2016 17:32:22 GMT (Hays Free Press)
Former NIU soccer star goalkeeper Amy Carr recovering from brain ...
Sat, 23 Jul 2016 01:54:00 GMT (DeKalb Daily Chronicle)
Personal Tragedy Leads to Effort for Brain Tumor Victims | News ...
Tue, 19 Jul 2016 16:12:22 GMT (Southern Pines Pilot)
Panama's Manuel Noriega to Have Surgery on Brain Tumor
Sat, 16 Jul 2016 19:23:10 GMT (New York Times)
Discover How Science and Technology are Driving Innovative Brain ...
Tue, 19 Jul 2016 19:04:33 GMT (PR Newswire (press release))

* Headlines are from industry sponsored news wires, medical journals and established news organizations from around the world . Please consider the source of the content when viewing the story.
  
 
Dani Saleh Brain Cancer Research Fund at UCLA


The Dani Saleh Brain Cancer Research Fund supports the brain cancer research collaboration between Dr. Timothy Cloughesy and Dr. Stan Nelson. This fund will directly support the work and training of a research fellow in Dr. Stan Nelson’s lab.

Dr. Nelson is Professor and Vice Chair of Human Genetics and Professor of Psychiatry at the David Geffen School of Medicine at UCLA.

UCLA Neuro-Oncology & SiliconMED Launch Online Tool Correlating Gene Expression Levels with Overall Survival of Brain Cancer Patients

Genomic analysis is a powerful new tool permitting unprecedented insights into how brain tumors form and has been enabled primarily through microarray technology. ProbeSetAnalyzer.com, a new web based tool, is aiming to help clinicians and researchers take the massive amount of data created by microarrays and better visualize gene expression levels and how they relate to the overall survival of brain cancer patients.

Most Popular
. Clinical Trials
. Probe Set Analyzer
. Our Team
. Brain Tumor Translational Resource
. Art of the Brain
. Personalized Medicine using Targeted Molecular Therapy
. Online Giving
. How our Glioblastoma Multiforme Patients Perform
Neuro-Oncology on Facebook

Spring/Summer 2014
UCLA Neuro-Oncology : Breakthroughs Spotlighting new discovery in brain cancer research.



It is time to include patients with brain tumors in phase I trials in oncology.
J Clin Oncol.


Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.
Neuro Oncol.


Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma.
Neuro Oncol.


Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery.
J Neurooncol.


Phase II study of aflibercept in recurrent malignant glioma: a north american brain tumor consortium study.
J Clin Oncol.



All Information content hearof is designed for educational purposes only and is not for the purpose of rendering medical advice or professional services. The information provided should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. Any specific questions you may have regarding an individual's medical condition should be directed to the individual's primary care physician or other attending physician. In addition, if you have or suspect you may have a health problem, you should consult your health care provider.

Portions Copyright (Search, Chart, Content Publishing Tools, Photography, ProviderIQ) 1998-2016 SiliconMED North America

ProviderIQ is a registered trademark of SiliconMED North America and used by permission.

Copyright © 2016 UCLA Neuro-Oncology Program | Timothly Cloughesy MD; Director
All Rights Reserved.

[Content Published:7/27/2016 6:27:01 AM PST]